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Abstract
Background: Successful gene therapy will require targeted delivery vectors capable of self-directed localization. In this
regard, the use of antibodies or single chain antibody fragments (scFv) in conjunction with adenovirus (Ad) vectors remains
an attractive means to achieve cell-specific targeting. However, a longstanding barrier to the development of Ad vectors
with genetically incorporated scFvs has been the biosynthetic incompatibility between Ad capsid proteins and antibody-
derived species. Specifically, scFv require posttranslational modifications not available to Ad capsid proteins due to their
cytoplasmic routing during protein synthesis and virion assembly.
Methodology/Principal Findings: We have therefore sought to develop scFv-targeted Ad vectors using a secreted scFv that
undergoes the requisite posttranslational modifications and is trafficked for secretion. Formation of the scFv-targeted Ad
vector is achieved via highly specific association of the Ad virion and a targeting scFv employing synthetic leucine zipper-
like dimerization domains (zippers) that have been optimized for structural compatibility with the Ad capsid and for
association with the secreted scFv. Our results show that zipper-containing Ad fiber molecules trimerize and incorporate
into mature virions and that zippers can be genetically fused to scFv without ablating target recognition. Most importantly,
we show that zipper-tagged virions and scFv provide target-specific gene transfer.
Conclusions/Significance: This work describes a new approach to produce targeted Ad vectors using a secreted scFv
molecule, thereby avoiding the problem of structural and biosynthetic incompatibility between Ad and a complex targeting
ligand. This approach may facilitate Ad targeting using a wide variety of targeting ligands directed towards a variety of
cellular receptors.
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Introduction
Successful gene therapy will require both rational vector
development and exploitation of disease-specific cellular physiol-
ogy to design targeted gene delivery vectors. Vectors based on
human adenovirus (Ad) serotypes 2 and 5 of species C continue to
show increasing promise as gene delivery vehicles due to several
key attributes: Ad vectors display in vivo stability and excellent gene
transfer efficiency to numerous dividing and non-dividing cell
targets, do not integrate into the host genome, and are rarely
linked to any severe disease in immunocompetent humans.
Further, production parameters for clinical grade Ad vectors are
well established. As of 2008, Ad vectors were employed in one-
fourth of gene therapy clinical trials worldwide [1]. However,
limited efficacy in clinical trials using Ad-based agents has clearly
exposed the need for vector modifications designed to provide
target cell-specific gene delivery and expression, thereby improv-
ing efficacy and safety.
Targeted gene delivery is ultimately predicated on the ability of
the vector to discriminate between target and non-target cells via
interaction with unique cell- or disease-specific surface markers.
Antibodies and recombinant antibody binding domains are
potentially useful agents to achieve cell-specific targeting, due to
their unparalleled affinity and specificity of binding to a wide
range of target cell surface markers. On this basis, the
development of Ad vectors with genetically incorporated anti-
body-derived moieties has been a long-standing goal. Genetic
capsid incorporation of several classes of attractive targeting
ligands, including single-chain antibodies (scFv) and growth
factors, has been severely hampered by the innate biosynthetic
incompatibilities between these targeting ligands and Ad capsid
proteins. Ad capsid proteins are translated and fold within the
reducing environment of the cytoplasm followed by nuclear
transport and virion assembly in the nucleus. In contrast,
translation, post-translational modification and correct folding of
scFv occur in the oxidizing environment of the endoplasmic
PLoS ONE | www.plosone.org 1 December 2009 | Volume 4 | Issue 12 | e8355reticulum, followed by trafficking to the cell surface via the Golgi
system and subsequent secretion [2]. Thus, cytoplasmic routing of
an Ad capsid-scFv fusion protein inhibits the formation of a
correctly folded scFv capable of antigen recognition while also
reducing Ad virion assembly and replication [3].
On this basis, we have developed a strategy to produce scFv-
targeted Ad vectors that retains the native secretory biosynthetic
pathway of standard available ‘‘off the shelf’’ scFv molecules. The
unique aspect of this approach is the genetic tagging of the Ad
capsid and the scFv with synthetic leucine zipper-like dimerization
domains that provide high affinity, selective interaction between
Ad particles and the scFv following lysis of the producer cells. In
this report, we outline the construction, rescue and targeting
characterization of a novel scFv targeted Ad vector, and
demonstrate that this approach can provide selective and target
antigen-dependent gene delivery via use of a traditional scFv
molecule.
Results
A Strategy for Coupling a Secreted scFv to Adenovirus
Using Leucine Zipper Heterodimers
The ability to use a commonly available ‘‘off-the-shelf’’
recombinant antibody species, especially those in scFv format,
for the purpose of Ad vector targeting would be highly
advantageous. To this end, we have developed a system that
maintains the divergent biosynthetic pathways of the antibody and
adenovirus components via use of a secreted scFv molecule
encoded by the vector. This design aspect requires that self-
assembly of the targeted Ad vector occurs following lysis of
producer cells (Fig. 1A). The ideal assembly mechanism between
the scFv and the Ad virion would provide stable, selective and
high-affinity association without forming aggregates. Further, the
linkage function would be based on genetically incorporable
peptide motifs that are small, soluble, and fully compatible with
scFv structure and antigen binding, as well as with Ad capsid
proteins. Based on these considerations, we chose to use a genetic
approach based on engineered heterodimerizing coiled-coil
protein structures derived from vitellogenin gene binding protein
(VBP), a leucine zipper DNA binding protein [4]. We hypothe-
sized that genetic tagging of the Ad virion and the scFv with a
single ‘‘zipper’’ dimerization domain from a heterodimerizing pair
would provide the stringent self-assembly properties required for
the formation of scFv-targeted Ad vectors (Fig. 1B). We selected
two pairs of heterodimerizing zipper domains based on size,
charge and heterodimerization properties (Fig. 1C). The 29-
residue E-E34/R-R34 zipper pair has been used to non-covalently
crosslink GFP to proteins that are not functional as genetic fusions,
and selectively forms heterodimers with a dissociation constant of
Kd=7 610
29 M and a Tm of 51.5uC [5,6]. We employed a second
43-residue zipper pair, EE12RR345L/RR12EE345L, that hetero-
dimerizes with a Tm of 73uC, with a corresponding dissociation
constant of Kd=1.3610
211 M [7]. For simplicity, E-E34, R-R34,
EE12RR345L and RR12EE345L zippers will also be referred to as E,
R, ER and RE, respectively.
Design of Fusion Proteins Containing Zipper Peptides
and scFv
Our targeting system is based on Ad vector targeting via scFv-
mediated binding to a cell surface molecule. On this basis, we
employed a scFv derived from the mouse monoclonal G28-5
antibody (denoted throughout as scFv G28-5) directed against
human CD40 [8]. The zipper-scFv G28-5 fusion molecules were
constructed to incorporate, from N- to C-terminus, a 21-residue
secretion signal peptide of the kappa-chain of human immuno-
globulin, a 4-residue helix cap sequence, one of the four zipper
sequences, a 14-residue flexible linker and the scFvG28-5 followed
by c-myc and 6His tags at the C-terminus (Fig. 1C). The four
zipper-scFv G28-5 variants were incorporated into shuttle vectors,
transferred into the E1 region of Ad5 genomes, and the resultant
viruses were used to express each zipper-scFv G28-5 variant in
A549 lung carcinoma cells. We confirmed the expression and
secretion of each zipper-scFv G28-5 protein via western blot
analysis of cell culture medium. As shown in Figure 2A, all four
zipper-scFv proteins were detected via an anti-penta-His primary
antibody in medium samples with molecular masses of approxi-
mately 39 kDa, consistent with the predicted mass of the full
length proteins. No corresponding bands were present in negative
control mock infected cells (data not shown). We next sought to
confirm that the addition of the zipper domains to scFv G28-5
does not interfere with antigen recognition. We performed ELISA-
based binding assays using metal affinity-purified zipper-G28-5
proteins and a recombinant form of the CD40 target receptor as
bait. As shown in Figure 2B, scFv G28-5 fused with the E-E34,R -
R34 and EE12RR345L zipper domains exhibited levels of binding
comparable to the parental G28-5 mAb. These data show that
zipper-tagged scFv G28-5 proteins are properly secreted and
soluble when expressed via an Ad vector and, most importantly,
retain native antigen recognition.
Incorporation of Zipper Peptides in to the Ad Capsid
We next sought to determine the optimal capsid locale and
genetic configuration for the display of zipper domains. We
considered the key issue of the structural compatibility of zipper
peptides at various capsid locales and selected the fiber as the site
of zipper domain incorporation. Heterologous peptides have
proven functional in the context of the Ad5 fiber C-terminus and
H-I loop as well as the C-terminus of knobless artificial fibers.[9–
13] On this basis, we incorporated each of the four zipper domains
into either the C-terminus or the H-I loop of the wild type fiber
protein. Also, a modified fiber protein containing extended peptide
linkers within the H-I loop was used for zipper peptide display.
Further, we also incorporated each zipper into the C-terminus of
two knob-deleted chimeric fibers, the fiber-fibritin fiber and the
566FF fiber [11,14,15]. The 373-residue fiber-fibritin chimeric
fiber [11] is comprised of the Ad5 fiber tail domain and two
amino-terminal repeats of the Ad5 shaft domain genetically fused
with eight C-terminal coiled-coil segments of the bacteriophage T4
fibritin protein. The 566FF fiber [14,15] contains the entire Ad5
fiber shaft fused to the 12th coiled-coil segment of fibritin. A total
of eighteen recombinant fiber genes were generated and then
screened on the basis of protein expression, trimer formation,
virion incorporation and the ability of the fiber-displayed zipper
domain to heterodimerize with its corresponding zipper domain.
To this end, expression plasmids encoding each zipper-containing
fiber protein were transfected into HEK 293 cells and fiber
expression and trimerization evaluated via western blot analysis.
Of the eighteen fibers, only the fiber with the R-zipper in the H-I
loop was not expressed at a level comparable to that of wild type
Ad5 fiber, and was not used further (Figure S1). We observed
decreased trimerization in fibers with zipper domains incorporated
into the Ad5 fiber C-terminus, including R-zipper and ER-zipper
containing fibers. Further, fibers with R- and ER-zippers encoded
within the H-I loop exhibited decreased trimerization as judged by
the lower ratio of trimeric to monomeric protein band intensity in
unboiled samples, and were not used further (Figure S1).
We next sought to determine the ability of the zipper-containing
fiber proteins to be incorporated into Ad virions using a fiber
Antibody Targeted Adenovirus
PLoS ONE | www.plosone.org 2 December 2009 | Volume 4 | Issue 12 | e8355Figure 1. Diagrams depicting our targeting strategy, fiber and scFv configuration, zipper sequences and vector genomes. (A)
Schematic of the proposed Ad vector targeting approach showing Ad-mediated scFv expression and secretion followed by cell lysis and Ad virion
release and extracellular formation of a targeted Ad vector/scFv complex. (B) Configuration of heterodimeric zipper domains, wherein one zipper
domain is genetically incorporated onto the C-terminus of the knobless 566FF fiber, and its counterpart is fused to the N-terminus of a recombinant
scFv molecule. (C) Peptide sequences of the two heterodimeric zipper pairs used. Each of the peptides comprising the pairs E?E34/R?R34, and
EE12RR345L/RR12EE345L can associate with its complimentary partner, thereby forming a stable heterodimer. The letters indicate the residue position
within each heptad repeat. Also shown is a molecular map of the zipper-scFv fusion proteins showing the N-terminus, IgG-derived secretion signal
peptide, a helix cap sequence, zipper sequence, a flexible linker and the scFvG28-5 followed by c-myc and 6His tags at the C-terminus. See main text
for additional details. (D) Simplified genomic map of AdLuc1566FF-R/E-G28-5 and AdLuc1566FF-ER/RE-G28-5 vectors showing the CMV/firefly
luciferase expression cassette in the deleted E1 region, the zipper-scFv G28-5 open reading frame in place of the 19 kDa protein locus in the E3
region, and zipper-566FF fiber molecule replacing the Ad fiber.
doi:10.1371/journal.pone.0008355.g001
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do this, 293 cells were transfected with the fiber-encoding plasmids
and then infected with an Ad vector which lacks the fiber gene in
its genome but contains the wild type fiber in the capsid supplied
by producer cells that express Ad5 fiber. Therefore, if functional,
the zipper-fiber proteins produced in the cells are expected to
incorporate into the capsids of the fiber-deleted virus progeny. We
then analyzed virions produced by this method by western blot to
determine capsid incorporation of transiently expressed zipper-
fibers. Consistent with the poor trimerization we observed, fibers
with zipper domains incorporated into the H-I loop were poorly
incorporated into mature virions, with the exception of the fiber
containing the E-zipper in the H-I loop (Figure S2). Fibers with
zippers incorporated at the fiber C-terminus showed moderate to
full incorporation, an interesting outcome in light of the relatively
poor trimerization observed for these fibers. The remainder of the
fibers showed capsid incorporation similar to that of Ad5 fiber
(Figures S2 and Table 1).
We next performed ELISA-based binding assays to determine
the ability of the fiber-incorporated zipper domains to form
heterodimers with the corresponding zipper-scFvG28-5 species.
Purified zipper-scFv G28-5 protein was adsorbed onto ELISA
plates followed by the addition of purified virions containing
zipper fibers or lysates from 293 cells transfected with zipper-fiber
protein expression plasmids. The formation of heterodimeric
fiber/scFv complexes was demonstrated by detection of bound
zipper-fiber proteins with an anti-fiber antibody or bound virions
with anti-Ad anti-serum. Of note, zipper-containing fibers with
poor trimerization and/or very low virion incorporation were not
tested. Importantly, the results of this binding analysis indicated
that maximum zipper heterodimer formation occurs with the
corresponding zipper-scFv when the R-R34 and EE12RR345L
zipper domains are located on the C-terminus of either the 566FF
fiber or the fiber-fibritin knob deleted fibers (Table 1). Based on
the overall performance of the 566FF fiber platform, we
considered the display of the R-R34 and EE12RR345L zipper
domains at the 566FF C-terminus to be the optimal configuration
for the capsid incorporation of zipper domains. In this regard,
Figure 3A shows both 566FF-R-R34 and 566FF-EE12RR345L
fibers form trimers (lanes 1 and 3) that were converted to
monomers upon heat denaturation (lanes 2 and 4), similar to wild
type fiber controls. We also examined incorporation of 566FF-R-
R34 and 566FF-EE12RR345L fibers in purified virions containing
only the modified fiber. As shown in Figure 3B, both 566FF-zipper
fibers were incorporated into mature virions; the 566FF-R-R34
fiber was incorporated fully (Figure 3B, lane 3) while the 566FF-
EE12RR345L was incorporated at a reduced level. Figure 3C shows
formation of heterodimeric fiber/scFv complexes with these fibers
contained in cell lysates from 293 cells transfected with fiber
expression vectors. Specific formation of heterodimers was
observed for the 566FF-R-R34 and 566FF-EE12RR345L fibers
and the corresponding zipper-scFv proteins (E-E34-scFv G28-5
and RR12EE345L-scFv G28-5, respectively). Importantly, forma-
tion of homodimeric complexes was not observed.
Secreted scFv Provides Antigen-Specific Ad Vector Gene
Transfer
We next designed two Ad5-based vectors to evaluate the ability
of our scFv-based targeting system to provide antigen-specific Ad
vector gene delivery. Recombinant Ad genomes were constructed
to encode a CMV promoter/firefly luciferase expression cassette
in the E1 region, the 566FF-R-R34 or 566FF-EE12RR345L fiber
and the complementary zipper-scFv G28-5 inserted into the intact
E3 region in the place of the deleted 19 kDa protein (Fig. 1D). The
resultant Ad vectors, designated AdLuc1566FF-R/E-G28-5 and
AdLuc1566FF-ER/RE-G28-5, were rescued in fiber–expressing
293F28 cells [12]. These vectors were then propagated in 293F28
cells and purified by standard methods and the presence of both
the zipper fibers and Ad5 fiber in purified virions was confirmed
via western analysis (Figure S3). To generate fully targeted virions,
Figure 2. Analysis of expression and binding properties of
secreted zipper-tagged scFv. (A) Western blot analysis of culture
medium from A549 human lung carcinoma cells transduced with Ad5
vectors encoding each zipper-scFv G28-5 molecule. Lanes denote the
zipper domain fused with each scFv. Culture medium was collected,
Laemmli buffer added, and samples boiled prior to SDS-PAGE and
western analysis with an anti-Penta-His antibody. Molecular mass
markers indicate kilodaltons. (B) ELISA-based binding assays using metal
affinity-purified zipper-G28-5 proteins. Each well contained 500 mgo f
CD40. Zipper-scFv G28-5 proteins were added to the wells at the
dilutions indicated. The positive control parental G28-5 mAb was added
at dilutions of 1/500, 1/2,500, 1/5,000 and 1/10,000 from a stock
solution of 0.15 mg/ml.
doi:10.1371/journal.pone.0008355.g002
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E-G28-5 or AdLuc1566FF-ER/RE-G28-5 vectors, and the cells
were maintained until full CPE was observed. In our system, the
progeny virions released into the culture medium would contain
only 566FF-zipper fibers and would form targeted complexes with
secreted zipper-scFv G28-5 antibodies present in the culture
medium (Fig. 1A). We next tested the ability of the AdLuc1566FF-
R/E-G28-5 and AdLuc1566FF-ER/RE-G28-5 vectors to provide
scFv-mediated targeted gene transfer to CD40-positive cells. We
exposed CD40-negative 293 cells and the CD40-positive
293.CD40 cell line [12] to culture medium containing Ad-
Luc1566FF-R/E-G28-5 or AdLuc1566FF-ER/RE-G28-5 vectors.
As shown in Figure 4A, the non-targeted Ad5Luc1 control vector
(MOI=10 vp/cell) provided robust transgene delivery as mea-
sured by firefly luciferase activity to both 293 and 293.CD40 cell
lines in a manner consistent with the similar levels of the CAR
receptor in both cell lines. In contrast, gene transfer of the targeted
AdLuc1566FF-ER/RE-G28-5 vector to 293.CD40 cells was
increased by up to 84-fold compared to CD40-negative 293 cells.
We observed a similar pattern with the AdLuc1566FF-R/E-G28-5
vector, whereby gene transfer to 293.CD40 cells was increased by
up to 175-fold compared to CD40-negative 293 cells (Fig. 4B). To
further confirm the capacity of the scFv-targeted vectors to deliver
cell-specific gene transfer, we performed blocking experiments
based on competitive inhibition using a purified form of the G28-5
scFv that is fused to an Fc domain (Fc-G28-5) [17]. As shown in
Figure 4C, gene transfer to 293.CD40 cells by untargeted
Ad5Luc1 control vector was not affected by the addition of free
Fc-G28-5. However, gene transfer of both targeted vectors was
blocked over 80% in the presence of 1.0 mg/ml free Fc-G28-5 and
over 90% at 10.0 mg/ml, confirming the role of CD40 and the
scFv-G28-5 in targeted gene transfer exhibited by these vectors.
Discussion
The goal of this study was to establish a genetic Ad vector
targeting platform that would allow the use of available complex
peptide ligands with high target affinity and specificity, but lack the
biosynthetic compatibility required for genetic fusion with Ad
capsid proteins. Capsid incorporation of several classes of complex
targeting ligands, including single-chain antibodies (scFv) and
secreted growth factors, has been severely hampered by the innate
biosynthetic incompatibilities between the ligand and Ad capsid
proteins, resulting in unstable or insoluble ligands and/or reduced
Ad replication [3]. With this limitation in mind, cytoplasmically
stable scFv molecules have been generated via the use of highly
stable antibody frameworks that can fold independently and
support antigen-binding structures (complementarity determining
regions or CDRs) (reviewed by M. Stocks[18]). The majority of
cytoplasmically stable scFv have been directed against intracellular
targets for therapeutic intervention. However, those that recognize
cell surface markers could, in theory, be genetically incorporated
into the Ad capsid for cell antigen-specific vector targeting. In this
regard, Hedley and colleagues genetically incorporated a cyto-
plasmically stable scFv into an artificial knob-deleted Ad fiber and
demonstrated targeted gene transfer in vitro to cells expressing an
artificial receptor containing the scFv epitope [15]. This work
established the principle that genetic fusion of a cytoplasmically
Table 1. Summary of expression, trimerization, capsid incorporation and dimerization of zipper-modified Ad fibers.
Site of zipper incorporation Zipper Expression Trimerization
Incorporation
into virions
Heterodimer binding
to zipper scFv
Homodimer binding
to zipper scFv
Ad5 fiber none +++ +++ +++ --
HI-loop E-E34 +++ ++ +++ -n t
R-R34 + - - nt nt
EE12RR345L +++ + - nt nt
RR12EE345L +++ ++ - nt nt
Fiber C-terminus E-E34 ++ + + + nt nt
R-R34 ++ + + nt nt
EE12RR345L ++ + ++ + -
RR12EE345L ++ ++ +++ nt nt
Extended HI loop E-E34 ++ +++ +++ nt nt
R-R34 ++ +++ +++ -n t
EE12RR345L ++ + +++ nt nt
RR12EE345L ++ ++ +++ --
C-terminus of fiber-fibritin chimera E-E34 +++ ++ +++ --
R-R34 +++ +++ ++ ++ -
EE12RR345L +++ +++ nt +++ -
RR12EE345L +++ +++ nt nt nt
C-terminus of 566FF fiber R-R34 +++ +++ +++ +++ -
EE12RR345L +++ +++ ++ ++ -
‘‘+++’’, -highly positive.
‘‘++’’, -positive.
‘‘+’’, -slightly positive.
‘‘-’’, -negative result.
‘‘nt’’, -not tested.
doi:10.1371/journal.pone.0008355.t001
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PLoS ONE | www.plosone.org 5 December 2009 | Volume 4 | Issue 12 | e8355Figure 3. Trimerization profiles of zipper-modified 566FF fiber proteins. (A) Western blot analysis of lysates of 293T cells transfected with
expression vectors expressing zipper-modified 566FF fiber proteins. Protein samples in Laemmli buffer were separated by SDS-PAGE with prior heat
denaturation by boiling (B, boiled) or without boiling (U, unboiled). Following transfer of proteins to PVDF membrane, proteins were then probed
with an anti-fiber monoclonal antibody that recognizes the fiber tail. Lanes 1 and 2 contains 566FF-R-R12 fibers, lanes 3 and 4 the 566FF-EE12RR345L
fibers and lanes 5 and 6 wild type Ad5 fiber. Fiber monomers (M) and trimers (T) are indicated. Molecular mass markers indicate kilodaltons. (B)
Western blot analysis of fibers from virions purified on 293 cells and containing a single genetically encoded fiber. Lane 2 contains WT Ad5 fiber, Lane
3 is 566FF-R and lane 4 is 566FF-ER. Each lane contained 5610
9 viral particles. (C) ELISA-based binding assay of zipper-tagged 566FF fibers with
zipper-scFv G28-5. Zipper-scFv proteins expressed by Ad vectors cells were purified by immobilized metal ion affinity chromatography and adsorbed
into wells of a 96-well ELISA plate. Dilutions of equal amounts of cell lysate from 293T cells transfected with plasmids encoding the 566FF-zipper
proteins were added to the wells. The formation of stable complexes was demonstrated by detection of the scFv-bound 566FF fiber proteins with an
anti-fiber 4D2 monoclonal antibody.
doi:10.1371/journal.pone.0008355.g003
Antibody Targeted Adenovirus
PLoS ONE | www.plosone.org 6 December 2009 | Volume 4 | Issue 12 | e8355Figure 4. Gene transfer of scFv-targeted vectors. Each panel shows firefly luciferase activity 24 hours following transduction. Gene delivery of
AdLuc1566FF-ER/RE-G28-5 vector (A) or AdLuc1566FF-R/E-G28-5 vectors (B) to CD40-negative 293 cells (white columns) or 293.CD40 cells (gray
columns) is shown. Targeted vector present in culture media of 293 producer cells was added to cells cultured in 24-well plates at volumes of 10 ml,
100 ml and 250 ml per well. A control vector, Ad5Luc1 containing an isogenic reporter gene cassette, was added at 10 vp/cell. (C) Luciferase activity in
293.CD40 cells 24 hours following transduction with AdLuc1566FF-ER/RE-G28-5 and AdLuc1566FF-R/E-G28-5 targeted vectors contained in 100 mlo f
culture media, as above. Free Fc-scFv G28-5 was used as a competitive inhibitor of CD40 binding and was added to the wells at the concentrations
indicated prior to vector addition. For all panels, each column is average of 4 replicates and error bar indicates standard deviation.
doi:10.1371/journal.pone.0008355.g004
Antibody Targeted Adenovirus
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antigen recognition, targeted gene delivery and that this approach
is dependent on a single cytoplasmic biosynthetic pathway. While
progress has been made toward a wider use of therapeutic
recombinant intrabodies through improved structural optimiza-
tion and rapid screening protocols, [19–23] the fact remains that
the repertoire of intrabodies directed against clinically relevant cell
surface markers is quite limited, and has hindered the develop-
ment of antibody-based Ad vector targeting.
A more common approach allowing Ad targeting with
biosynthetically incompatible molecules such as scFv has been
the construction of heterologous bispecific molecules that cross-
link the Ad virion to alternative cell surface targets. These adapters
have typically been diabodies [24,25], fusions of a scFv and the
soluble ectodomain of CAR (sCAR-scFv) [8,26,27] or sCAR fused
to growth factors [28], and are produced separately and mixed
with the Ad vector prior to use. However, in the context of
conditionally replicating Ad vectors (CRAds), this approach is
unsuitable since the targeting moiety is lost following the initial
infection. On this basis, we and others advanced the notion of Ad
targeting based on expression of secreted paracrine adapter
molecules encoded in the vector genome as a means of retaining
targeting capacity of conditionally replicating Ad vectors (CRAds)
[29–32].
This study was focused on the employment of a standard
recombinant single chain antibody, as members of this antibody
class are widely available and capable of targeting the largest
repertoire of cell-surface molecules. Rather than attempting to
alter intracellular trafficking and/or biosynthesis of the targeting
ligand, we employed a secreted adapter approach conceptually
similar to that previously used for CRAd agents. This system relies
on the native intracellular routing and secretion of the scFv with
subsequent self-assembly of the targeted Ad vector occurring
following lysis of producer cells during vector upscaling. This
design aspect was considered critical to the applicability of this
system to the widest variety of currently available ‘‘off-the-shelf’’
targeting ligands.
Central to the success of this approach was the use of linking
moieties structurally and functionally compatible with both the Ad
capsid and the targeting ligand. In this regard, we sought out
linking motifs that are small, stable and soluble so as to minimize
potential negative effects on targeting ligand function. Additional
design requirements included association of Ad virions and
targeting ligand without self-aggregation of the system components
or binding to natural cellular proteins. For these reasons, protein
A-, biotin/avidin- and chemical crosslinking-based approaches
were not considered. With a view towards in vivo targeting, another
critical consideration was the affinity between the linking moieties
in order to minimize the potential for dissociation of the targeted
Ad/scFv complex. We have previously shown that Ad vector
targeting in vitro [26] and in vivo [33] using sCAR-scFv adapters is
enhanced by increasing the affinity between the trimeric Ad5 fiber
knob and the sCAR component by using a trimeric form of the
sCAR-scFv, establishing that increased affinity between vector and
ligand directly translates to improved transductional targeting. In
this regard, the affinity of the Ad2 and Ad5 fibers for CAR has
been determined, with dissociation constants in the range of 1-to-
23 nM, depending on the methods used [34–36]. A similar
dissociation constant (Kd=3 nM) has been reported for the S11
anti-fiber knob scFv used in some diabody strategies [31,32,37].
On this basis, we specifically sought a linking strategy that could
provide increased affinities between vector and scFv ligands not
possible with sCAR-scFv or other approaches. To this end, we
followed an approach based on optimized heterodimeric coiled-
coil protein pairs that exhibit the aforementioned design
requirements as well as heterodimer dissociation constants that
extend into the picomolar range.
In this report we demonstrate the feasibility of employing
heterodimer peptide zipper pairs to crosslink a genetically
modified Ad vector and a secreted targeting ligand. Specifically,
we have shown that two distinct zipper peptides can be genetically
fused to the C-terminus of knob-deleted fibers, and that this capsid
proved compatible with zipper function and vector amplification.
It is possible, however, that further optimization of zipper display
at the fiber capsid locale may be required to achieve the maximum
utility of this approach. Equally important, we show that zipper-
tagged scFv molecules are properly secreted and soluble when
expressed via an Ad vector and retain native antigen recognition.
Further, we demonstrate that scFv-targeted Ad vectors provide
gene delivery that is dependent on target antigen recognition.
We have previously shown antibody-mediated Ad vector
targeting in vivo via the use of heterologous adapter molecules in
the form of bi-specific antibody conjugates [38,39] or scFv-
containing fusion proteins [27,33,40]. While effective in vivo, these
two-component systems rely on separate production and purifica-
tion of the Ad vector and the adapter molecule, followed by
mixing of the two components before administration. In this
regard, it is generally recognized that a single component vector
would likely be more suitable for regulatory approval and clinical
use. The approach we describe here is a step toward development
of a targeted Ad vector wherein the vector and targeting ligand are
produced simultaneously within the same culture conditions, and
could therefore mimic the production schemas of single compo-
nent systems. In this regard, our future work will seek to establish
optimal methods by which targeted Ad vectors produced in this
system will be purified. An important design aspect of our system is
that the targeted vectors are ablated for CAR binding, thereby
eliminating the possibility of ectopic vector localization in vivo to
CAR-expressing tissues if the targeted complex is disrupted. As a
consequence, the initial rescue and propagation of the vectors is
inefficient in 293 cells. For preclinical work, this issue is
circumvented via the use of 293 cells that stably express Ad5
fiber, yielding an intermediate vector species that is then upscaled
using standard 293 cells. At the present time, however, it is unclear
whether a technically similar approach could be used for
production of clinical grade CAR-ablated vectors.
In conclusion, this Ad targeting approach provides a novel way
to circumvent the problem of structural and biosynthetic
incompatibility between Ad and complex targeting ligands, and
could facilitate Ad targeting to a wide variety of clinically
important cell populations using novel targeting ligands including
recombinant antibodies and growth factors.
Materials and Methods
Cell Lines
The Ad5 DNA-transformed 293 and 293T human embryonic
cells line were purchased from Microbix (Toronto, Ontario,
Canada). The 293F28 and 293/hCD40 cell lines are derivatives of
293 cells which express either Ad5 wild-type fiber (for virus
propagation) or human CD40 as previously described[12]. 293F28
cells were maintained with 600 mg/ml Zeocin (Invitrogen), and the
293/CD40 cell with 1000 ug/ml G418. Human lung adenocar-
cinoma A549 cells were obtained from the American Type
Culture Collection (ATCC, Manassas, Va.) and maintained in
DMEM with 5% (v/v) fetal calf serum. All 293 and 293-derived
cell lines were propagated in a 50:50 mixture of DMEM/F-12
media supplemented with 10% (v/v) fetal calf serum (FCS),
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(100 mg/ml) at 37uCi n5 %C O 2 in humidified conditions.
Genetic Engineering
Enzymes. Restriction endonucleases and T4 DNA ligase
were purchased from New England Biolabs (Beverly, MA).
Polymerase chain reaction (PCR) was performed with Pfu DNA
polymerase (Stratagene, La Jolla, CA).
Construction of recombinant plasmids. An Ad shuttle
vector suitable for modification of the C-terminus of the fiber
protein was designed by subcloning an AgeI-MfeI-fragment of the
previously described pBS.F5LLBamHI plasmid [41] into the
pKan3.1 shuttle vector. The resultant plasmid, pKan-FbLL-
BamHI, contains a modified fiber gene whose 39 end is fused
with a sequence encoding a short peptide linker (G4S)3 with a
terminal BamHI site. The gene is flanked with DNA sequences
adjacent to the wild type fiber gene in the Ad5 genome.
An Ad shuttle vector suitable for modification of the C-terminus
of the fiber-fibritin protein was designed by subcloning an AgeI-
MfeI-fragment of the previously constructed pXK.FF.LL plasmid
[12] into the pKan3.1 shuttle vector. Plasmid pXK.FF.LL
contains the gene encoding the chimeric Ad5 fiber-phage T4
fibritin protein [11] fused with a C-terminal flexible linker. The
resultant pKan-FF-LL-BamHI contains a modified fiber-fibritin
gene whose 39 end is fused with the sequence encoding a short
peptide linker (G4S)3 with a terminal BamHI site. The gene is
flanked with DNA sequences adjacent to the wild type fiber gene
in the Ad5 genome. To incorporate the zipper peptides into the C-
terminus of the 566FF fiber [14], we employed shuttle plasmid
pKan.566FF-LL-BamHI which contains a chimeric fiber com-
prised of the tail and shaft domains of Ad5 fiber fused to the 12th
coiled-coil segment of fibritin followed by a peptide linker (G4S)3
with a terminal BamHI site. The 566FF gene is flanked with DNA
sequences adjacent to the wild type fiber gene in the Ad5 genome.
Four double-stranded DNA templates corresponding to each of
the four zipper peptides were assembled with pairs of oligonucle-
otides, which formed partial duplexes upon annealing via
complementary sequences (see Table S1; underlined nucleotides
are complementary). The recessed 39-ends of the resultant
duplexes were then filled in a PCR-like reaction employing Pfu
DNA polymerase (Stratagene, La Jolla, CA) to generate blunt-
ended molecules. BamHI sites (underlined) and stop codons
(bolded) were added to these blunt-ended templates by PCR
using the following primer pairs: E-E34 (fwd 59-C G GGATCC-
CGTGCAGCTTTCCTGGAGAA, rev 59-C G GGATCCTTA-
GATGTTCTCACATCGTCCT); R-R34 (fwd 59-C G GGATCC-
CGTGCAGCTTTCCTGGAGAA, rev 59-CGGGATCCTTA-
GATGTTCCGACATCGTCCT); EE12RR345L (fwd 59-CG-
GGATCCCTGGAGATCGAGGCAGCTT, rev 59-CGGGATCC-
TTACAGAGGTCCGTAACGAGTT); RR12EE345L (fwd 59- CG-
GGATCCCTGGAGATCCGTGCAGCTT, rev 59-CGGGATCC-
TTACAGAGGTCCGTAACGAGTT). The generated PCR
products encoding the zipper peptides were cleaved with BamHI
and cloned into BamHI-digested pKan-LL-BamHI, pKan-FF-LL-
BamHI and pKan.566FF-LL-BamHI resulting in shuttle plasmids
pKan-LL-E, pKan-LL-R, pKan-LL-ER pKan-LL-RE and pKan-
FF-LL-E, pKan-FF-LL-R, pKan-FF-LL-RE, pKan-FF-LL-RE,
pKan.566FF-LL-E and pKan.566-LL-RE
To create mammalian expression plasmids encoding the zipper-
containing fibers, AgeI-MfeIo rAgeI-SwaI fragments for fiber or
fiber-fibritin, respectively, from the above fiber shuttle vectors
were subcloned into similarly digested expression plasmid pVSII
[17]. Plasmid pVSII encodes the Ad5 fiber with a unique MfeI site
downstream from the 39 end of the fiber open reading frame. The
resulting fiber expression plasmids were designated pVS-LL-E,
pVS-LL-R pVS-LL-RE, pVS-LL-ER and pVS-FF-LL-E, pVS-
FF-LL-R, pVS-FF-LL-RE, pVS-FF-LL-ER pVS-566FF-R and
pVS-566FF-EN.
To generate Ad5 fibers containing zipper peptides within the H-
I loop of the fiber knob domain, we constructed an expression
vector, pVS.DHI-BaeI, which contains the Ad5 fiber gene with the
H-I loop sequence partially deleted and replaced with a BaeI
restriction site. This was done by subcloning an AgeI-MfeI fragment
of the previously described Ad fiber shuttle vector pKan3.1DHI-
BaeI [17] into AgeI-MfeI-linearized pVS. Of note, BaeI is a type I
restriction enzyme and excises its recognition sequence leaving
unique, non-complementary sticky ends in the digested vector,
thereby facilitating directional cloning of inserts. Sticky ends
complementary to those in BaeI-digested pVS.DHI-BaeI were
added to all four zipper-encoding templates generated previously
(see above) by using a sticky end PCR protocol with two primer
sets (see Table S2). The resultant sticky-end PCR products
encoding each zipper were denatured, annealed and ligated into
BaeI-cut pVS.DHI-BaeI. This resulted in a set of four pVS.DHI-
BaeI-derived expression vectors: pVS-HI-E, pVS-HI-R, pVS-HI-
ER and pVS-HI-RE. To create corresponding fiber shuttle vectors
containing zipper peptides in the H-I loop, AgeI-MfeI fragments
from pVS-HI-series expression vectors were ligated into AgeI-MfeI-
digested pKan3.1 shuttle vector to yield shuttle plasmids pKan-
HI-E, pKan-HI-R, pKan-HI-RE and pKan-HI-ER.
To generate expression vectors containing genes for fibers with
zippers incorporated into an extended H-I loop, we used previously
designed fiber shuttle plasmid pHI-PB40 [13] as starting material.
Plasmid pHI-PB40 encodes a modified Ad5 fiber with a genetic
extension of the HI-loop with a 40aa sequence from the Ad5
penton base comprised of the 20 upstream residues and 20
downstream residues that flank the native RGD tripeptide motif,
but with the RGD replaced by a BaeI restriction site. An AgeI-MfeI-
fragment of pHI-PB40 was subcloned into AgeI-MfeI-linearized
pVS, resulting in expression vector pVS-PB40(BaeI). Sticky ends
complementary to those in BaeI-digested pVS-PB40(BaeI) were
added to all four zipper-encoding templates generated previously
by using a sticky end PCR protocol using two primer sets (see Table
S2). The resultant sticky ended PCR products were denatured,
annealed and cloned into BaeI-cleaved pVS-PB40(BaeI). This
resulted in a set of four pVS-PB40-derived expression vectors:
pVS-PB40-E, pVS-PB40-R, pVS-PB40-ER and pVS-PB40-RE.
To create corresponding fiber shuttle vectors containing zipper
peptides in the extended H-I loop, AgeI-MfeI fragments from pVS-
PB40-series expression vectors were ligated into AgeI-MfeI-digested
pKan3.1 shuttle vector to yield shuttle plasmids pKan-PB40-E,
pKan-PB40-R, pKan-PB40-RE and pKan-PB-ER.
Shuttle vectors for transfer of zipper-scFv transgenes into the Ad5
E3 region are based on plasmid pZErO-2E3-6.9 that was
constructed by ligating HindIII-cut pZErO-2 (Invitrogen) to a
6.9 kb HindIII fragment from fiber-deleted genome plasmid
pVL5000. This fragment contains the entire E3 region, the deleted
fiber region replaced by a SwaI site and E4 orf6. In order to modify
the E3 region in pZErO-2E3-6.9 for insertion of transgenes, a
2.7 kb EcoR1 fragment containing the native E3 region was ligated
into ApaI-digested pZErO-2 to yield plasmid pZErO-2E3-2.7. Next,
the 19 kD gene within pZErO-2E3-2.7 was deleted by digesting
with XbaI and MfeI. A 360 bp PCR product containing XbaI/MfeI
compatible ends and a unique HpaI restriction site was ligated into
XbaI/MfeI-digested pZErO-2E3-2.7 resulting in plasmid pZErO-
2E3D19k-HpaI. Blunt-ended PCR products encoding each of
four zipper-scFv cDNAs were ligated into HpaI-digested pZErO-
2E3D19k-HpaI to yield plasmids pZErO-2E3d19k-sp-E-G28,
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pZErO-2E3d19k-sp-RE-G28. To insert transgenes into the
pZErO-2E3-6.9 shuttle plasmid, ApaI-XhoI fragments from the four
pZErO-2E3D19k-HpaI–based plasmids above were ligated into
similarly digested pZErO-2E3-6.9, resulting in shuttle vectors
pZErO-2E3-6.9-E-G-28, pZErO-2E3-6.9-R-G-28, pZErO-2E3-
6.9-ER-G-28, and pZErO-2E3-6.9-RE-G-28.
Generation of recombinant adenovirus. Recombinant Ad
genomes incorporating only modified fiber genes were derived by
homologous DNA recombination in Escherichia coli BJ5183 with
SwaI-linearized genome plasmid pVK700 and fiber shuttle vectors
listed above as described previously [10]. pVK700, a derivative of
pTG3602 [42], contains an Ad5 genome with full E1, E3, and fiber
gene deletions and a firefly luciferase reporter gene driven by the
cytomegalovirusimmediateearlypromoterinplaceofthe E1region.
Recombinant Ad genomes incorporating both modified fiber
and zipper-modified scFv were created by two separate homolo-
gous recombinations in Escherichia coli BJ5183 with SwaI-linearized
genome plasmid pVL700DE3, an Ad5 genome with full E1, E3
and fiber gene deletions, but with a unique SwaI restriction site in
place of the deleted E3 and fiber regions. Plasmid pVL700DE3
was created by homologous recombination between SwaI-cut
pVK700 and plasmid pZErO-2DE3.SwaI, a shuttle vector
containing a SwaI-containing short linker sequence between the
genomic regions flanking the E3 region and the fiber region.
Plasmid pZErO-2DE3.SwaI is a derivative of plasmid pZErO-
2E3-6.9 and was created by SmaI digestion of pZErO-2E3-6.9 and
subsequent ligation of a 59-GGGAAATTTAAATTCCC-39
duplex linker containing a SwaI site (underlined). To insert the
zipper-scFv cDNAs into the E3 region, the first homologous
recombination was performed between SwaI-digested pVL700DE3
and SwaI-digested shuttle vectors pZErO-2E3-6.9-E-G-28, pZErO-
2E3-6.9-R-G-28, pZErO-2E3-6.9-ER-G-28, and pZErO-2E3-6.9-
RE-G-28. The resulting fiber-deleted genome plasmids containing
the zipper-scFv in the E3 region were produced: pVL700DE3-E-
G28-5, pVL700DE3-R-G28-5, pVL700DE3-ER-G28-5 and
pVL700DE3-RE-G28-5. These genomes were then digested with
SwaI and recombined with EcoRI-linearized fiber shuttle vectors
pVS-566FF-R and pVS-566FF-EN to generate final genomes
AdLuc1566FF-R/E-G28-5 and AdLuc1566FF-ER/RE-G28-5.
Ad vectors AdLuc1566FF-R/E-G28-5 and AdLuc1566FF-ER/
RE-G28-5 were generated by transfection of 293F28 cells with
PacI-digested Ad genome vectors as described previously [12].
293F28 cells stably express the wild-type Ad5 fiber, so the rescued
virions at this point contained both wild-type fibers and 566FF-
zipper fibers. These dual-fiber viruses were purified by two rounds
of equilibrium centrifugation in CsCl gradients by a standard
protocol [43]. To generate virions with only 566FF-ziper fibers, we
transduced 293 cells with purified dual-fiber AdLuc1566FF-R/E-
G28-5 or AdLuc1566FF-ER/RE-G28-5 vectors, and the cells
were maintained until full CPE was observed and virions were
purified as above. Viral particle (v.p.) concentration for all Ad
vectors was determined at 260 nm by the method of Maizel [44]
by using a conversion factor of 1.1610
12 v.p./absorbance unit.
Expression of Zipper-scFv Proteins
The coding sequence for anti-CD40 scFv G28.5 [8] was fused
with the sequences encoding each of the four zipper peptides and a
signal peptide of the k–chain of human immunoglobulin using a
sticky-end PCR strategy (see Figure 1). The fusion genes were then
ligated between the PmeI and BamHI sites in the Ad shuttle vector
pAdenoVator-CMV5 (Q-Biogene) and homogonously recom-
bined into a Ad5 genome pAdenoVatorDE1/DE3 contained in
a bacterial plasmid. The four resultant genomes were used to
rescue Ad vectors of interest in 293 cells as above. The viruses
generated were employed to direct the expression of the zipper-
ligand proteins in human lung carcinoma A549 cells. Zipper-scFv
proteins expressed by these Ad vectors were purified by
immobilized metal ion affinity chromatography and then used in
ELISA-based binding assays.
Expression of Zipper-Modified Fiber Proteins
Recombinant fiber genes were assembled in various Ad shuttle
vectors and then transferred to the pVSII fiber expression plasmid
as described above and previously [17]. Each transfection mixture
consisted of 4 ug of endotoxin-free fiber-encoding pVSII expres-
sion plasmid in HEPES buffer containing 20 ul of DOTAP
(Roche) transfection reagent in a total volume of 200 ul. This
mixture was then diluted into 2 ml of OPTI-MEM media and
applied directly to 293T cells. Cells were maintained under
standard condition for 4 hours after which 3 ml complete media
was added. At 48 hours post-transfection medium was removed
and cells were collected in 200 ul Cell Culture Lysis Buffer
(Promega) and cell debris was removed via centrifugation. Lysates
were used for enzyme-linked immunosorbent assay (ELISA) and
for western analysis.
Western Blot Analysis
Protein samples were diluted into Laemmli buffer and
incubated at room temperature (unboiled samples) or 95uC for 5
minutes (boiled samples) and loaded onto a 7.5% or 4–20%
gradient SDS-polyacrylamide gel (Bio-Rad, Hercules, CA).
Following electrophoretic protein separation, proteins were
electroblotted onto a PVDF membrane. For detection of
recombinant fibers, the 4D2 primary monoclonal antibody
(recognizing the Ad5 fiber tail domain) was diluted 1/3000 (Lab
Vision, Freemont CA). Zipper-scFv G28-5 proteins were detected
via an anti-Penta-his primary antibody (Qiagen). Immunoblots
were developed by addition of a secondary horseradish peroxi-
dase-conjugated anti-mouse or anti-rabbit immunoglobulin anti-
bodies at a 1/3000 dilution (Dako Corporation, Carpentaria, CA),
followed by incubation with 3-39-diaminobenzene peroxidase
substrate, DAB (Sigma Chemical Company, St. Louis, MO).
ELISA
The wells of 96-well Nunc Immuno-Plates (Fisher Scientific,
Pittsburgh, Pa.) were coated overnight at 4uC with the target
protein diluted in 50 mM carbonate buffer (pH 8.6) in a total
volume of 100 ml. Target proteins were zipper-scFv G28-5
proteins expressed in A549 cell and purified from culture media
or recombinant human CD40/Fc (R&D Systems, Minneapolis,
MN). The unsaturated surface of the wells was then blocked for
1 h at room temperature by the addition of 200 ml of blocking
buffer (Tris-buffered saline [TBS] with 0.05% Tween 20 and 0.5%
casein) to each well. The blocking buffer was replaced with 100 ml
of zipper-scFv G28-5 protein or 293T cell lysates containing
zipper-modified fiber proteins diluted in binding buffer (TBS with
0.05% Tween 20 and 0.05% casein). Plates were incubated at
room temperature for 1 h and then were washed four times with
washing buffer (TBS with 0.05% Tween 20). Bound fiber proteins
or Ad particles were detected by incubation for 1 h at room
temperature with anti-fiber 4D2 MAb or anti-Ad2 polyclonal
antibodies, respectively. The wells were washed four times with
washing buffer; either goat anti-mouse immunoglobulin G or goat
anti-rabbit immunoglobulin antibodies conjugated with horserad-
ish peroxidase (Dako) were then added, and incubation was
continued for 1 h. The color was developed with a Sigma FAST o-
phenylenediamine dihydrochloride tablet kit as recommended by
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with an EL800 plate reader (Bio-Tek Instruments, Winooski, Vt.).
Gene Transfer Assays
For gene transfer experiments 293 and 293-CD40 cells were
plated in wells of 24-well plates and were transduced for 1 hour at
37uC with Ad5Luc1 at an MOI of 10 vp/cell or with various
volumes (10–250 ml) of culture media containing scFv-targeted Ad
vectors AdLuc1566FF-R/E-G28-5 and AdLuc1566FF-ER/RE-
G28-5 in a total of 300 ml of infection media containing 2% fetal
calf serum. Following transduction, cells were rinsed in infection
media, and were maintained at 37uC in an atmosphere of 5%
CO2. Cells were harvested 24 hours post-transduction and gene
transfer was determined using a luciferase activity assay system
(Promega, Madison, WI) according to the manufacturer’s
instructions. For experiments containing blocking agents, recom-
binant Fc-G28.5 scFv was incubated at 0.1, 1.0, and 10 mg/ml
final concentration with the cells at 37uC in transduction media 15
minutes prior to the addition of the virus. Following the
transduction, cells were rinsed with transduction media to remove
unbound virus and blocking agent, and were maintained at 37uC
in an atmosphere of 5% CO2.
Supporting Information
Figure S1 Western blot analysis of expression and trimerization
of zipper-modified fiber proteins. The lysates of 293 cells
transfected with plasmid vectors expressing zipper-modified
proteins were separated by SDS-PAGE with or without prior
denaturation by boiling. The proteins were then probed with anti-
fiber antibody. Vectors used are shown at the top. E, R, ER, and
RE indicate the peptide zippers incorporated into the proteins.
WT, wild type Ad5 fiber, B and UB stand for boiled and unboiled
samples, respectively.
Found at: doi:10.1371/journal.pone.0008355.s001 (0.42 MB TIF)
Figure S2 Incorporation of zipper-modified fiber proteins into
Ad virions. 293 cells were transfected with fiber-encoding plasmids
and then infected with an Ad vector which lacks the fiber gene in
its genome but contains the wild type fiber in the capsid supplied
by 293F28 producer cells. Purified Ad virions were analyzed by
western blot using anti-Ad5 fiber tail antibody. The blot shows
heat-denatured monomeric fibers only. Localization of zipper
peptides within the fibers or fiber-fibritin (FibF) chimeras is shown
at the top. wt, wild-type Ad5 fiber.
Found at: doi:10.1371/journal.pone.0008355.s002 (0.45 MB TIF)
Figure S3 Incorporation of dual fibers into Ad virions. Purified
Ad virions were separated on a 7.5% SDS-PAGE gel and then
analyzed by western blot using anti-Ad5 fiber tail antibody. The
blot shows heat-denatured monomeric fibers only. Lane 2 contains
purified AdLuc1566FF-R/E-G28-5 virions that contain both WT
and 566FF-R fibers after propagation in 293F28 cells. Lane 3
contains purified Ad5 virions propagated in 293 cells. Lane 4
contains lysate from 293F28 cells infected with AdLuc1566FF-R/
E-G28-5 showing the presence of both WT and 566FF-R fibers in
the cells. Lanes 2 and 3 contained 1x10e10 viral particles. Due to
the size similarity between the WT Ad5 fiber and 566FF-ER, these
fibers migrate as a single band and are not shown.
Found at: doi:10.1371/journal.pone.0008355.s003 (0.29 MB TIF)
Table S1 Oligonucleotides used for assembling sequences
encoding peptide zippers. When partially annealed, the underlined
complementary nucleotides form a duplex within each zipper
sequence. The recessed 39-ends of the resultant duplexes are then
filled in a PCR-like reaction employing Pfu DNA polymerase to
generate blunt-ended molecules.
Found at: doi:10.1371/journal.pone.0008355.s004 (0.03 MB
DOC)
Table S2 Primers sets for PCR-based addition of sticky ends to
zipper cDNAs.
Found at: doi:10.1371/journal.pone.0008355.s005 (0.05 MB
DOC)
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